CONMED Corp — Director's Dealing 2021

Nov 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CONMED Corp (CNMD)
CIK: 0000816956
Period of Report: 2021-11-02

Reporting Person: KENNEDY JOHN JED (Group Executive Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-02	Common Stock	M	862	$41.93	Acquired	8237	Direct
2021-11-02	Common Stock	S	862	$146.668	Disposed	7375	Direct
2021-11-02	Common Stock	M	5100	$59.96	Acquired	12475	Direct
2021-11-02	Common Stock	S	1822	$147.057	Disposed	10653	Direct
2021-11-02	Common Stock	S	3278	$147.57	Disposed	7375	Direct
2021-11-02	Common Stock	M	1800	$78.76	Acquired	9175	Direct
2021-11-02	Common Stock	S	928	$147.512	Disposed	8247	Direct
2021-11-02	Common Stock	S	872	$148.313	Disposed	7375	Direct
2021-11-02	Common Stock	M	1700	$97.69	Acquired	9075	Direct
2021-11-02	Common Stock	S	1700	$148.596	Disposed	7375	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-02	Options To Purchase Common Stock	$41.93	M	862	Disposed	2027-03-01	Common Stock (862)	Direct
2021-11-02	Options To Purchase Common Stock	$59.96	M	5100	Disposed	2028-03-01	Common Stock (5100)	Direct
2021-11-02	Options To Purchase Common Stock	$78.76	M	1800	Disposed	2029-03-01	Common Stock (1800)	Direct
2021-11-02	Options To Purchase Common Stock	$97.69	M	1700	Disposed	2030-03-02	Common Stock (1700)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.24 to $147.01. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.34 to $147.31. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.36 to $147.96. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.94 to $147.88. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.02 to $148.59. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.10 to $148.82. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F7: The stock options were granted under the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period.

F8: The stock options were granted under the Company's 2018 Long-Term Incentive Plan and generally vest in equal amounts over a five year period